請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group

PR Newswire (美通社)

更新於 13小時前 • 發布於 14小時前 • PR Newswire

TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables the combined organization to offer a full suite of bioprocessing products, solutions, and services across both research and industrial applications.

The integration provides Leadgene Biosolutions with a clear direction and expanded opportunities in global bioprocessing and cell-based research markets. The company will continue to advance its signature technologies, including the S.NEST®, C.NEST®, and C.BIRD™ microbioreactor systems - platforms recognized as the only solutions on the market capable of delivering true high-throughput 24- and 96-well culture with fully adjustable mixing, supported by integrated DO, pH, OCR, and ECAR monitoring. These technologies remain central to the organization's long-term vision, and future product families and expanded applications are being developed to support broader bioprocessing workflows and long-term metabolism assays.

"Building on proven strengths in bioprocessing, the integration gives Leadgene Biosolutions the expanded expertise to advance our long-term plans with refined focus." said Cheng-Han (Charles) Tsai, CEO of Leadgene Biosolutions. "The group now delivers one of the most complete end-to-end bioprocessing ecosystems, enabling customers to move faster from early research to clinical-ready workflows," added Dr. Chasel Yung-Chun Chuang, Chairman of Leadgene Biomedical.

All existing contracts, demo schedules, warranties, and support services remain fully intact. Gradual brand updates will introduce a more unified and forward looking identity that reflects the group's core vision.

Leadgene Biosolutions website:

Leadgene Biomedical website:

查看原始文章

All-new Hyundai NEXO Achieves Maximum Five-Star Rating in Euro NCAP Safety Assessment

PR Newswire (美通社)

TM Forum Releases Core Network High-Reliability AN Solution Package, Leading a New Paradigm of Autonomous Networks

PR Newswire (美通社)

Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...